OGI Stock Analysis: Buy, Sell, or Hold?

OGI - Organigram Global Inc. Common Shares

Pharmaceutical Preparations
$0.96
0.00 (-0.02%) ▼
5d: +1.63%
30d: -2.48%
90d: -30.63%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 12, 2026 7d

Get Alerted When OGI Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: OGI shows positive signals but monitor for confirmation. Market pricing in 10.0% decline. Moderate conviction.
See Forward Earnings Fair Value & Price Prediction →

In-depth Analysis How we analyze

Valuation Analysis: OGI is currently trading at $0.96, which is considered fair relative to its 30-day fair value range of $0.91 to $1.00. From a valuation perspective, the stock is trading at a discount (Forward PE: 43.8) compared to its historical average (60.2). Remarkably, the market is currently pricing in an annual earnings decline of 10.0% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, OGI is in a strong downtrend. The price is approaching resistance at $0.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: OGI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (83th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $8.80 (+812.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position FAIR
Historical Trading Range $0.91 - $1.00
Company Quality Score 60/100 (HOLD)
Options IV Signal 83th percentile (EVENT RISK)
Volume Confirmation HIGH
Confidence Score 67.3%

All Signals

  • NEUTRAL: Price in fair range
  • BEARISH: Options expensive (IV 83th percentile)
  • BULLISH: Strong technical setup (60/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 812.5% below Wall St target ($8.80)

Trading Range Analysis

30-Day Trading Range $0.91 - $1.00
Current vs Trading Range FAIR
Expected Move (7 Days) ±$0.19 (19.5%)

Support & Resistance Levels

Support Level $0.90
Resistance Level $0.97
Current Trend Strong Downtrend
Technical data as of Aug 3, 2026

Fundamental Context

Forward P/E (Next Year Est.) 43.84
Wall Street Target $8.80 (+812.5%)
Revenue Growth (YoY) -8.9%
Profit Margin -9.2%
Valuation Discount vs History -10.0% cheaper
PE vs Historical 43.8 vs 60.2 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -10.0% (market-implied from PE analysis)
1-Year Target $0.87 (-10%)
2-Year Target $0.78 (-19%)
3-Year Target $0.70 (-27%)
3-Yr Target (if PE normalizes) (PE: 44→60) $0.97 (+0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 43.8, Growth: -66.7%) $0.70 (+-27%)
Base: (SPY PE: 20.7, Growth: -66.7%) $0.33 (-66%)
Bear: (PE: 17.6, Growth: -66.7%) $0.28 (-71%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 43.8 to 60.2
Stabilization Target: $1.32 (+37.3%)
PE Expansion Potential: +37.3%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: August 04, 2026 11:26 AM ET
Data refreshes hourly during market hours. Next update: 12:26 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for OGI.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I…
STRONG BUY
25 analysts
$211 58 HOLD
ZTS
Zoetis Inc
BUY
20 analysts
$112 49 HOLD
AQST
Aquestive Therapeutics I…
STRONG BUY
9 analysts
$9 59 HOLD
LNTH
Lantheus Holdings Inc
STRONG BUY
13 analysts
$113 46 HOLD
UTHR
United Therapeutics Corp…
STRONG BUY
15 analysts
$663 48 HOLD

More Analysis for OGI

OGI Technical Chart OGI Price Prediction OGI Earnings Date OGI Investment Advisor OGI Fair Price Analyzer OGI Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals